| Bioactivity | AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM. |
| Invitro | AGN 210676 (Compound 23) also is a less potent agonist for recombinant human prostaglandin receptors hEP3A and hDP with EC50s of 153 nM and 7749 nM, respectively. AGN 210676 is useful for the treatment of glaucoma, ocular hypertension, inflammatory bowel disease, and the other diseases or conditions disclosed herein[1]. |
| Name | AGN 210676 |
| CAS | 910562-15-1 |
| Formula | C23H29NO5S |
| Molar Mass | 431.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Old, David W, et al. SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS. US20070203222A1. |